Differentiation between *Mycobacterium bovis* BCG-Vaccinated and *M. bovis*-Infected Cattle by Using Recombinant Mycobacterial Antigens

BRYCE M. BUDDLE,†* NATALIE A. PARLANE,† DENISE L. KEEN,† FRANK E. ALDWELL,‡ JOHN M. POLLOCK,§ KEN LIGHTBODY,∥ AND PETER ANDERSEN∥

AgResearch, Wallacetown Animal Research Centre, Upper Hutt, New Zealand; Veterinary Sciences Divison, Department of Agriculture for Northern Ireland, Belfast, United Kingdom; and Department of TB Immunology, Statens Serum Institut, DK-2300 Copenhagen, Denmark

Received 6 May 1998/Returned for modification 27 July 1998/Accepted 22 September 1998

Tuberculosis continues to be a worldwide problem for both humans and animals. The development of tests to differentiate between infection with *Mycobacterium tuberculosis* or *Mycobacterium bovis* and vaccination with *M. bovis* BCG could greatly assist in the diagnosis of early infection as well as enhance the use of tuberculous vaccines on a wider scale. Recombinant forms of four major secreted proteins of *M. bovis*—MPB59, MPB64, MPB70, and ESAT-6—were tested in a whole-blood gamma interferon (IFN-γ) assay for differentiation between cattle vaccinated with BCG and those experimentally infected with *M. bovis*. BCG vaccination induced minimal protection in the present study, with similar numbers of animals infected with *M. bovis* in BCG-vaccinated and nonvaccinated groups. Following vaccination with BCG, the animals produced moderate IFN-γ responses to bovine purified protein derivative (PPDB) but very weak responses to the recombinant antigens. Cattle from both the BCG-vaccinated and nonvaccinated groups which were *M. bovis* culture positive following challenge produced IFN-γ responses to PPDB and ESAT-6 which were significantly stronger than those observed in the corresponding *M. bovis* culture-negative animals. IFN-γ responses to MPB59, MPB64, and MPB70 were significantly weaker, and these antigens could not discriminate between vaccinated animals which develop disease and the culture-negative animals. The results of the study indicate that of the four antigens tested in the IFN-γ assay, only ESAT-6 would be suitable for differentiating BCG-vaccinated animals from those infected with bovine tuberculosis.

Tuberculosis in humans and animals continues to cause major health problems on a global scale. Human tuberculosis accounts for eight million cases of clinical disease and three million deaths annually (22) and is predominantly caused by *Mycobacterium tuberculosis*. Bovine tuberculosis is a major cause of economic loss and represents a significant zoonotic infection (8). *Mycobacterium bovis* is the etiological agent of bovine tuberculosis and is closely related to *M. tuberculosis* within the tuberculosis complex. An important control strategy for the prevention of these diseases is the use of effective vaccines. Vaccination of cattle against bovine tuberculosis has particular application in countries which cannot afford the traditional "test and slaughter" control approach and in those which have wildlife reservoirs of *M. bovis* infection.

The *M. bovis* bacillus Calmette-Guérin (BCG) vaccine, an attenuated strain of *M. bovis*, has been widely used for control of human tuberculosis despite controversy over its protective efficacy (2). In cattle, BCG has been used in a series of trials, with various degrees of protection against *M. bovis* challenge (4, 5, 19). However, a major constraint in the use of attenuated mycobacterial vaccines such as BCG is that vaccination of humans or cattle interferes with detection of tuberculosis by means of the tuberculin skin test. The development of tests which can distinguish between infection with *M. tuberculosis* or *M. bovis* and vaccination with BCG could greatly assist in the diagnosis of early infection as well as enhance the use of tuberculous vaccines on a wider scale.

The sensitivity of diagnostic tests could be enhanced by using alternative blood tests rather than conventional skin tests. Blood tests based on in vitro detection of gamma interferon (IFN-γ) released in response to mycobacterial antigens have been suggested as an improved method for detecting human (7) and bovine (25) tuberculosis. The whole-blood IFN-γ assay for cattle has been shown to be a robust and effective assay for measuring cell-mediated immune responses to *M. bovis* antigens in cattle (25). The specificity of the tests could be improved by using selected secreted mycobacterial proteins which have a restricted genetic distribution or markedly different levels of expression between BCG and virulent strains of the tuberculosis complex. ESAT-6, a recently identified low-molecular-weight secreted antigen, has a restricted species distribution, being found in *M. tuberculosis* and *M. bovis* but not in BCG (12). This antigen is an early and dominant T-cell target during tuberculosis in experimental animals (1, 3) and during *M. bovis* infection in cattle (20). MPB64 is restricted to the tuberculosis complex of mycobacterial species and can be found in *M. tuberculosis*, *M. bovis*, and some, but not all, substrains of BCG (13). This protein elicits delayed-type hypersensitivity reactions in sensitized guinea pigs (9) and lymphocyte proliferation responses in patients with human tuberculosis (23). MPB70, originally identified as a unique product of *M. bovis* (16), also occurs in *M. tuberculosis* and BCG but is expressed at a low level in some BCG strains. MPB59 is highly conserved between pathogenic and environmental mycobacterial species and is a dominant product in mycobacterial culture.

* Corresponding author. Mailing address: AgResearch, Wallacetown Animal Research Centre, P.O. Box 60-063, Upper Hutt, New Zealand. Phone: 64 44 5286089. Fax: 64 44 5281300. E-mail: buddelb@agresearch.cri.nz.
† Present address: Department of Microbiology, Otago University, Dunedin, New Zealand.
filtrates. MPB59 has been shown to induce delayed-type hypersensitivity reactions in sensitized guinea pigs (17).

The experimental model of tuberculosis established with cattle allows the study of immune responses following BCG vaccination and *M. bovis* infection in a natural host. Intratracheal challenge of cattle with a low dose of *M. bovis* has previously been found to result in the majority of nonvaccinated and a small number of BCG-vaccinated animals developing tuberculous lesions (4, 5). In this study, using a whole-blood IFN-γ assay, we evaluated recombinant mycobacterial antigens for their ability to distinguish between BCG-vaccinated and *M. bovis*-infected cattle.

**MATERIALS AND METHODS**

**Animals.** Twenty-four Friesian cross 5- to 6-month-old calves were obtained from tuberculosis-free accredited herds from an area of New Zealand free of infection. The calves grazed on pasture in a high-security isolation unit. Some of the calves had transient reactions to avian purified protein derivative (PPD) in the IFN-γ test prior to vaccination. Twelve of the calves which were randomly selected were vaccinated subcutaneously in the left side of the neck with 5 × 10^8 CFU of BCG Pasteur 1173P2 and revaccinated in a similar manner 7 weeks later. A group of 12 nonvaccinated calves served as controls. Twelve weeks after the initial vaccination, blood samples were collected from vaccinated and nonvaccinated animals. Fifteen weeks after the initial vaccination, nine animals from each of the BCG-vaccinated and nonvaccinated groups were challenged intratracheally with a low dose (10^7 CFU) of virulent *M. bovis*. The three nonchallenged calves from each group were kept in a separate paddock within the high-security isolation unit. Sixteen weeks after challenge, blood samples were collected for the IFN-γ assay and a tuberculin skin test was carried out. Animals were skin tested by intradermal injection in the right side of the neck with 0.1 ml containing 1 μg of bovine PPD (PPDB; Ministry of Agriculture and Forestry, Central Animal Health Laboratory, Upper Hutt, New Zealand). The injection site was first clipped, and then the thickness of the skin fold was measured with calipers. The skin fold thickness before injection was compared with that 72 h later. A skin test response was considered positive when there was at least a 3-mm increase in skin fold thickness (26). Two to three weeks later, all animals were killed and examined for tuberculous lesions, and pulmonary lymph nodes were collected for mycobacterial culture. The methods of vaccination, *M. bovis* challenge, necropsy, and processing of tissues for bacteriology and histopathology have been described in detail previously (4).

**Antigens.** (i) Recombinant MPB59, MPB64, and MPB70 were prepared as described previously (15). Briefly, the recombinant proteins were expressed in *Escherichia coli* by using the vector pRSET C (Invitrogen, Leek, The Netherlands) and purified by metal affinity column chromatography with Talon resin (Clontech, Cambridge, United Kingdom). (ii) Recombinant ESAT-6 was produced in *E. coli* XL1 blue by using a construct based on the vector pET28a and purified by metal affinity chromatography as described previously (11). (iii) PPDs used in the IFN-γ test were prepared from *Mycobacterium avium* (PPD) and *M. bovis* (PPDB) and were obtained from CSL Limited (Melbourne, Australia). (iv) The nonmycobacterial antigens keyhole limpet hemocyanin and ovalbumin were obtained from Sigma Chemical Co. (St. Louis, Mo.).

**IFN-γ assay.** The in vitro release of IFN-γ from whole-blood cultures was determined by a method described previously (4). Briefly, heparinized blood was dispensed in eight 1-ml aliquots and 70 μl of either phosphate-buffered saline, preservative-free PPD, or PPDB (14 μg/ml final concentration); the four recombinant mycobacterial antigens separately (MPB59, MPB64, MPB70, and ESAT-6; 2 μg/ml final concentration); or a pool of these four antigens with each antigen at a final concentration of 2 μg/ml. Titration of these recombinant mycobacterial antigens at final concentrations of 2, 4, and 8 μg/ml in whole-blood cultures from *M. bovis*-infected cattle had previously shown that 2 μg/ml was the optimum concentration for obtaining IFN-γ responses. The blood cultures were incubated for 24 h at 37°C in a humidified atmosphere of 5% CO₂ in air, after which the plasma supernatants were harvested from each well. The supernatants were assayed for IFN-γ with a sandwich enzyme-linked immunosorbent assay (ELISA) kit (CSL Limited). Positive and negative controls were included in all plates, and there was very little variation between plates. A titration of recombinant bovine IFN-γ showed a linear relationship between concentrations of IFN-γ and optical density (OD) units (450 nm). Samples in the IFN-γ ELISA were run in duplicate. IFN-γ responses to antigens were expressed as OD indices (ODI) and were calculated as follows: ODI = OD for the antigen sample OD for the phosphate-buffered saline sample.

**Statistical analyses.** The numbers of mycobacteria isolated were compared by analysis of variance. IFN-γ responses of different animal groups and with different antigens were analyzed by analysis of variance on log-transformed data. Correlations between IFN-γ responses to PPDB and ESAT-6 and skin test responses were calculated by using Pearson’s correlation.

---

**RESULTS**

**Protection against challenge with *M. bovis*.** The intratracheal inoculation of nonvaccinated cattle with a low dose of virulent *M. bovis* resulted in the development of macroscopic lesions in five of the nine animals. These lesions were observed in the pulmonary lymph nodes of the five animals and in the lungs of three of the animals. Lesions were usually numerous in affected lymph nodes and ranged from 1 to 10 mm in diameter, while lung lesions were found in low numbers (2 to 10 per affected lung) and were 2 to 3 mm in diameter. *M. bovis* was isolated from all of these lesions but not from any pulmonary nodes without lesions.

BCG vaccination induced little protection, and macroscopic lesions were observed in the pulmonary lymph nodes of three BCG-vaccinated animals which had been challenged with *M. bovis* and in the lungs of one of these animals (Table 1). The lesions were similar in appearance to those seen in the nonvaccinated animals. *M. bovis* was isolated from all of the lesions from the BCG-vaccinated animals as well as from the pulmonary lymph nodes of two animals from this group which had been challenged with *M. bovis* but had no macroscopic lesions. Microscopic tuberculous-like lesions were observed in a pulmonary lymph node of one of these two animals. No significant

---

**TABLE 1. Comparison of IFN-γ responses to PPDB and ESAT-6 with skin test responses to PPDB in cattle challenged with *M. bovis* 16 weeks previously**

| Animal¹ | Tuberculous lesions² | IFN-γ response (ODI)³ | Skin test response (mm)⁴ |
|---------|----------------------|-----------------------|--------------------------|
| Nonvaccinated | | |
| Challenged, culture positive | + + | 100.0 | 100.0 | 17 |
| 1 | + + | 80.6 | 55.9 | 20 |
| 2 | + + | 80.4 | 56.7 | 24 |
| 3 | + + | 64.1 | 35.2 | 16.5 |
| 4 | + + | 54.7 | 13.1 | 24 |
| Challenged, culture negative | | | |
| 5 | | 24.1 | 4.0 | 11 |
| 6 | | 3.3 | 2.5 | 0 |
| 7 | | 3.1 | 2.7 | 0 |
| 8 | | 2.7 | 1.4 | 0 |
| Nonvaccinated | | | |
| Challenged, culture positive | + + | 113.6 | 30.9 | 19 |
| 9 | + + | 95.1 | 28.6 | 20.5 |
| 10 | + + | 80.6 | 22.5 | 13.5 |
| 11 | + + | 62.5 | 52.7 | 14.5 |
| 12 | + + | 46.0 | 17.3 | 7.5 |
| BCG vaccinated | | | |
| Challenged, culture positive | + + | 69.4 | 7.3 | 4 |
| 13 | + + | 32.1 | 10.3 | 1.5 |
| 14 | + + | 18.4 | 5.3 | 5.5 |
| 15 | + + | 8.0 | 1.3 | 2 |
| Nonvaccinated | | | |
| Challenged, culture positive | + + | 31.8 | 7.0 | 8 |
| 16 | + + | 12.7 | 3.0 | 8.5 |
| 17 | + + | 9.9 | 2.8 | 11.5 |

¹ Culture positive, *M. bovis* cultured from tissues at necropsy; culture negative, no *M. bovis* cultured.
² +, macroscopic tuberculous lesions; +, only microscopic tuberculous lesions; −, no tuberculous lesions.
³ Measured by ELISA.
⁴ Increase in skin thickness measured 72 h after intradermal injection of PPDB.
difference in the numbers of mycobacteria isolated from the lung and pulmonary lymph nodes of the nonvaccinated and BCG-vaccinated groups was observed. No mycobacteria were isolated from nonchallenged animals from the nonvaccinated and BCG-vaccinated groups.

**IFN-γ responses after BCG vaccination.** Levels of IFN-γ released from PPDB-stimulated blood cultures peaked at 4 weeks after the initial BCG vaccination (Fig. 1). Revaccination of calves with BCG resulted in a marked increase in the levels of IFN-γ released from stimulated cultures, and these high levels persisted for at least 8 weeks after revaccination. The testing of different recombinant mycobacterial antigens at 12 weeks after the initial BCG vaccination (5 weeks after revaccination) corresponded to a time point at which the highest levels of IFN-γ were released from PPDB-stimulated cultures.

Blood cultures from BCG-vaccinated animals produced moderate IFN-γ responses to PPDA and PPDB but very weak responses to the recombinant mycobacterial antigens (Fig. 2). Although the mean IFN-γ responses to the recombinant antigens were all below an ODI of 3.5, the levels for the recombinant antigens except for MPB70 were significantly higher than those for the nonvaccinated animals ($P < 0.05$). However, IFN-γ responses to both PPDA and PPDB for the BCG-vaccinated animals were significantly stronger than those to the recombinant mycobacterial antigens ($P < 0.05$). The response to the pooled recombinant antigens was very similar to that to MPB59 alone.

To determine whether BCG-vaccinated cattle nonspecifically responded to antigens, blood cultures from six BCG-vaccinated and six nonvaccinated animals were set up 2 weeks later in wells containing 2 μg of keyhole limpet hemocyanin or ovalbumin per ml, and the levels of IFN-γ were measured. No significant differences in the IFN-γ responses to these two antigens between the BCG-vaccinated and nonvaccinated groups were observed.

**IFN-γ responses after M. bovis infection.** IFN-γ responses to recombinant mycobacterial antigens were measured at the final bleed (16 weeks after M. bovis challenge) to determine the relationship between these responses and active M. bovis infection. In the nonvaccinated group, IFN-γ responses to all antigen preparations for the five M. bovis-infected animals were all significantly stronger than for the seven M. bovis culture-negative animals from the same group (combined nonchallenged and M. bovis-challenged, culture-negative animals) ($P < 0.05$ [Fig. 3a]). However, the IFN-γ responses to PPDA,
PPDB, ESAT-6, and the pooled recombinant antigens were all significantly stronger than the responses to MPB59, MPB64, and MPB70 ($P < 0.05$).

In the BCG-vaccinated group, IFN-γ responses to PPDA, PPDB, ESAT-6, and pooled antigen preparations were all significantly stronger for the five $M. bovis$-infected animals than for the seven $M. bovis$ culture-negative animals from the same group ($P < 0.05$ [Fig. 3b]). In contrast to the nonvaccinated group, IFN-γ responses to MPB59, MPB64, and MPB70 for the BCG-vaccinated group were not significantly different for the culture-positive and the culture-negative animals.

Following challenge with $M. bovis$, the IFN-γ response to the pooled antigen preparation was similar to that for the individual mycobacterial antigen with the greatest response, ESAT-6, for both the nonvaccinated and BCG-vaccinated animals.

A comparison of IFN-γ responses to PPDB and ESAT-6 with skin test responses to PPDB is shown in Table 1. Very strong positive correlations between the IFN-γ responses to PPDB and ESAT-6 and between the IFN-γ and the skin test responses to PPDB were observed in the nonvaccinated animals. The coefficients for correlation between IFN-γ responses to PPDB and ESAT-6, IFN-γ response to PPDB and skin test PPDB response, and IFN-γ response to ESAT-6 and skin test PPDB response were 0.924, 0.904, and 0.698, respectively, for the 12 nonvaccinated animals and 0.698, 0.719, and 0.690, respectively, for the 12 BCG-vaccinated animals. All of these correlations were positive and significant ($P < 0.05$).

Based on the Office International des Epizooties standard for a positive skin test (a ≥3-mm increase in skin thickness), positive responses were detected in five of five $M. bovis$ culture-positive calves from both the nonvaccinated and BCG-vaccinated groups. For the culture-negative animals, positive responses were detected in one of four and two of four challenged calves from the nonvaccinated and BCG-vaccinated groups, respectively, and in zero of three and three of three nonchallenged calves from the nonvaccinated and BCG-vaccinated groups, respectively (Table 1).

**DISCUSSION**

Widespread use of tuberculosis vaccines in domestic animals depends on the development of diagnostic tests which can readily differentiate between vaccinated and tuberculosis-infected individuals. The present study used a whole-blood IFN-γ assay to detect immune responses to different mycobacterial antigens in BCG-vaccinated and $M. bovis$-infected cattle. Since vaccination of cattle with BCG induced little protection in this study, immune responses to selected mycobacterial antigens could be measured in BCG-vaccinated animals which subsequently developed an infection with $M. bovis$.

The majority of the vaccinated calves produced moderate responses to PPDB and PPDA in the IFN-γ assay but very weak responses to the recombinant mycobacterial antigens. Sixteen weeks after challenge with $M. bovis$, there were marked differences in IFN-γ responses to recombinant mycobacterial antigens in the nonvaccinated and BCG-vaccinated groups of animals that were culture positive. In the nonvaccinated group, an infection with $M. bovis$ induced strong IFN-γ responses to ESAT-6 (mean, 52.2 ODI units) which were comparable to those for PPDB, while IFN-γ responses to MPB59, MPB64, and MPB70 were weak to moderate (means ranged from 7.8 to 18.8 ODI units). The responses to all of these mycobacterial antigens were significantly greater for the culture-positive animals than for culture-negative animals from the same group. In contrast, in the BCG-vaccinated group ESAT-6 was the only recombinant mycobacterial antigen for which the IFN-γ responses were significantly greater for the culture-positive animals than for the culture-negative animals. This interesting finding indicates that a reagent based on ESAT-6 may discriminate active disease from exposure to $M. bovis$ and no infection.

The disparity in responses to the different mycobacterial antigens between culture-positive and culture-negative animals from the two groups could be related to the stage of the $M. bovis$ infection. Pollock and Andersen (20) recently showed that cattle in the early stages of experimental infection were characterized by strong IFN-γ responses directed predominantly against the low-molecular-mass ESAT-6. Cattle in later stages of experimental infection (16 weeks postinfection) exhibited a broader recognition of antigens of various molecular masses. Cattle with field cases of bovine tuberculosis preferentially recognized low-molecular-mass antigens, which is characteristic of animals in the early stages of infection. There is a suggestion from the present study that the $M. bovis$ infections in the BCG-vaccinated animals were at an early stage, since two of the $M. bovis$-infected animals which had been vaccinated had no macroscopic tuberculous lesions and one of these had microscopic tuberculous lesions. Secondly, in a previous study (4), the IFN-γ responses to PDDB in $M. bovis$-infected cattle which had previously been vaccinated with BCG peaked 2 months after corresponding responses observed in $M. bovis$-infected animals which were not vaccinated.

It is unlikely that the pulmonary isolates from $M. bovis$-infected animals were BCG, since no $M. bovis$ isolates were recovered from pulmonary lymph nodes of BCG-vaccinated cattle which had not been challenged. Furthermore, in three vaccination-challenge cattle studies (4–6) in which $M. bovis$ isolates were typed by molecular techniques, all of the pulmonary isolates corresponded to the challenge strain and not to BCG. No tuberculous lesions were seen in any of the studies in which BCG-vaccinated animals had not been challenged.

The reason that BCG induced no or little protection in the present trial is not clearly understood. However, some of the calves had transient reactions to PPDA in the IFN-γ assay prior to vaccination, suggesting exposure to environmental mycobacteria (data not shown). Prior exposure to environmental mycobacteria has been proposed as an explanation for the failure of BCG to induce protection in a number of human tuberculosis vaccine trials (2). In two earlier cattle trials where animals had no sensitization to PPDA prior to BCG vaccination, significantly fewer BCG-vaccinated animals than nonvaccinated animals developed tuberculous lesions following challenge (4, 5). In these two trials, in which BCG vaccination induced protection, the mean IFN-γ responses to PPDB following initial vaccination were stronger than in the present trial and in one other trial where there was no protection (6). However, for individual animals, there has been no correlation between the strength of the IFN-γ response to PPDB postvaccination and subsequent protection.

Although IFN-γ responses to the recombinant mycobacterial antigens in the present study were very weak following vaccination with BCG, the responses of the BCG-vaccinated animals were still significantly stronger than those of the nonvaccinated animals. The result for MPB59 could be expected since the gene for MPB59 is found in BCG strains and in one study 78% of human BCG vaccinees recognized MPB59 at the cellular level (23). In addition, T-cell responses to MPB59 in cattle could be stimulated by environmental mycobacteria as well as by $M. bovis$ (14). In contrast, the genes for MPB64 and ESAT-6 are not present in BCG Pasteur (12, 18), and MPB70 is expressed only at low levels by this strain of BCG (10). The most likely explanation is that there is a low level of cross-reactivity between these antigens and those from BCG Pasteur.
since it did not appear that the BCG-vaccinated animals non-
specifically responded to other antigens. There have been re-
ports of cross-reactivity between mycobacterial antigens. MPT64
has been shown to have regions of some sequence similarity to
the antigen 85 family members (24). A second possibility is that
since the recombinant antigens were expressed in E. coli, very
low concentrations of E. coli antigens or lipopolysaccharide
may be present in the antigen preparations, and these may
cross-react with antigens from BCG. However, it is important
to note that the IFN-γ responses to the recombinant antigens
in the BCG-vaccinated animals were very weak.

IFN-γ responses to the pooled recombinant mycobacterial
antigen preparation were very similar to the strongest response
in the BCG-vaccinated animals. These findings indicate that ESAT-6 should be
used for the ESAT-6 IFN-γ responses of all of the culture-negative animals (14).
A second possibility is that the vaccine in BCG-vaccinated animals need to be tested to confirm
these results.

In conclusion, the strong correlation between the IFN-γ responses to ESAT-6 and those to PPDB in M. bovis-infected and noninfected cattle confirmed previous findings (20, 21) that ESAT-6 would be a very useful reagent for specific diagnosis of bovine tuberculosis. IFN-γ responses to ESAT-6 were very weak in calves following vaccination with BCG, contrast-
ing with consistently strong IFN-γ responses to ESAT-6 in M. bovis-infected animals for both nonvaccinated and BCG-vacci-
cinated groups. These findings indicate that ESAT-6 should be a suitable antigen for use in diagnostic tests for differentiating between BCG-vaccinated and M. bovis-infected cattle.

ACKNOWLEDGMENTS

We thank Gary Yates and Carol Wilson for the bacteriology, Geoff
de Lisle for pathological examinations, and Lilian Morrison for statistical
analyses.

We are grateful to Ministry of Agriculture and Forestry Policy and the
British Council for financial assistance.

REFERENCES

1. Andersen, P., A. B. Andersen, A. L. Sorensen, and S. Nagai. 1995. Recall of
long-lived immunity to Mycobacterium tuberculosis infection in mice. J. Im-
munol. 154:3359–3372.
2. Bloom, B. R., and P. E. M. Fine. 1994. The BCG experience: implications for
future vaccines against tuberculosis. p. 531–557. In B. R. Bloom (ed.), Tu-
berculosis: pathogenesis, protection, and control. American Society for Mi-
crobiology, Washington, D.C.
3. Brandt, L., T. Oettinger, A. Holm, A. B. Andersen, and P. Andersen. 1996.
Key epitopes on ESAT-6 antigen recognized in mice during the recall of
protective immunity to Mycobacterium tuberculosis. J. Immunol. 157:3527–
3533.
4. Biddle, B. M., G. W. de Lisle, A. Pfeiffer, and F. E. Aldwell. 1995. Immuno-
ological responses and protection against Mycobacterium bovis in calves vac-
cinated with a low dose of BCG. Vaccine 13:1123–1130.
5. Biddle, B. M., D. D. Keen, A. Thomson, G. Jowett, A. R. McCarthy, J. Heslop,
G. W. de Lisle, J. L. Stanford, and F. E. Aldwell. 1995. Protection of cattle
from bovine tuberculosis by vaccination with BCG by the respiratory or
subcutaneous route, but not by vaccination with killed Mycobacterium vacci.
Res. Vet. Sci. 59:10–16.
6. Biddle, B. M., F. E. Aldwell, and D. N. Wedlock. 1995. Vaccination of cattle
and possums against bovine tuberculosis, p. 111–115. In F. Griffin and G. de
Lisle (ed.), Tuberculosis in wildlife and domestic animals, Otago Conference
Series no. 3. University of Otago Press, Dunedin, New Zealand.
7. Converse, P. J., S. L. Jones, J. Astemborski, D. Vlahov, and N. M. H.
Graham. 1997. Comparison of a tuberculin interferon-γ assay with the
tuberculin skin test in high-risk adult: effect of human immunodeficiency virus
infection. J. Infect. Dis. 175:723–729.
8. Daborn, C. J., and J. M. Grange. 1993. HIV/AIDS and its implications for
control of animal tuberculosis. Br. Vet. J. 149:405–417.
9. Haga, S., R. Yamaguchi, S. Nagai, K. Matsuo, A. Yamazaki, and R. M.
Nagai. 1999. Delayed type hypersensitivity to a recombinant mycobac-
terial antigen, MPB64, in guinea pigs sensitized to Mycobacterium tu-
berculosis or Mycobacterium bovis BCG. J. Leukoc. Biol. 57:221–225.
10. Harboe, M., and G. Nagai. 1984. MPB70, a unique antigen of Mycobacterium
bovis BCG. Am. Rev. Respir. Dis. 129:452–454.
11. Harboe, M., A. A. Malin, H. S. Dockrell, H. G. Wiker, G. Urvud, A. Holm,
M. C. Jørgensen, and P. Andersen. 1998. B-cell epitopes and quantification of
the ESAT-6 protein of Mycobacterium tuberculosis. Infect. Immun. 66:
717–723.
12. Harboe, M., T. Oettinger, H. G. Wiker, L. Rosenkrands, and P. Andersen.
1996. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tubercu-
losis and virulent Mycobacterium bovis and for its absence in Myco-
bacterium bovis BCG. Infect. Immun. 64:16–22.
13. Li, H., J. C. Uslstrup, T. Ø. Jonassen, K. Melby, S. Nagai, and M. Harboe.
1993. Evidence for absence of the MPB64 gene in some strains of Myco-
bacterium bovis BCG. Infect. Immun. 61:1730–1734.
14. Lightbody, K. A., R. M. Girvin, D. A. Pollock, D. P. Mackie, S. D. Neill, and
J. M. Pollock. 1998. Recognition of a common mycobacterial T-cell epitope
in MPB59 of Mycobacterium bovis. Immunology 93:314–322.
15. Lightbody, K. A., R. A. Skuce, S. D. Neill, and J. M. Pollock. 1998. Myco-
bacterial antigen-specific antibody responses in bovine tuberculosis: an
ELISA with potential to confirm disease status. Vet. Rec. 142:295–300.
16. Nagai, S., J. Matsumoto, and T. Nagasuga. 1981. Specific skin-reactive
protein from culture filtrate of Mycobacterium bovis BCG. Infect. Immun.
53:1152–1160.
17. Nagai, S., H. G. Wiker, M. Harboe, and M. Kinomoto. 1991. Isolation and
partial characterization of major protein antigens in the culture fluid of
Mycobacterium tuberculosis. Infect. Immun. 59:372–382.
18. Oettinger, T., and A. B. Andersen. 1994. Cloning and B-cell-epitope mapping
of MPT64 from Mycobacterium tuberculosis H37Rv. Infect. Immun. 62:2058–
2064.
19. O’Reilly, L. M., and C. J. Daborn. 1995. The epidemiology of Mycobacterium
bovis infections in animals and man: a review. Tubercle Lung Dis. 76(Suppl.
3):171–186.
20. Pollock, J. M., and P. Andersen. 1997. The potential of the ESAT-6 antigen
secreted by virulent mycobacteria for specific diagnosis of tuberculosis. J.
Infect. Dis. 175:1251–1254.
21. Ravignione, M. C., D. E. Snider, and A. Kochi. 1995. Global epidemiology of
tuberculosis: morbidity and mortality of a worldwide epidemic. JAMA 273:
220–226.
22. Roche, P. W., J. A. Tricas, D. T. Avery, T. Fifis, H. Billman-Jacobe, and W.
J. Britton. 1994. Differential T cell responses to mycobacteria-secreted
proteins distinguish vaccination with Bacille Calmette-Guerin from infection
with Mycobacterium tuberculosis. J. Infect. Dis. 170:1326–1330.
23. Wiker, H. G., S. Nagai, M. Harboe, and L. Ljungqvist. 1992. A family of
cross-reacting proteins secreted by Mycobacterium tuberculosis. Scand. J.
Immunol. 36:307–319.
24. Wood, P. R., L. A. Corner, J. S. Rothel, C. Baldock, S. L. Jones, D. B.
Cousins, B. S. McCormic, B. R. Francis, J. Creeper, and N. E. Tweedie.
1995. Manual of standards for diagnostics tests and vaccines, p.
287–296. Office International des Epizooties, Paris, France.